Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Date:11/1/2013

NORTH LIBERTY, Iowa, Nov. 1, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen).  Based on the results of the meeting, KemPharm believes the completed and ongoing clinical, non-clinical and CMC development programs will allow for the submission of a New Drug Application (NDA) for KP201 in the third quarter of 2014.

During the meeting, representatives from the FDA reviewed KemPharm's current portfolio of data for KP201, including the recently completed bioequivalence and "steady-state" pivotal clinical studies.  It was determined that the final data package, as proposed by KemPharm, would support a potential 505(b)(2) filing pathway without any additional efficacy, toxicology or safety data being required.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "The positive feedback we received from the Agency re-affirms prior discussions related to our clinical and non-clinical program for KP201 and our plan to pursue an NDA via the 505(b)(2) pathway. Based on their advice, we are extremely confident in our plan to submit an NDA by the third quarter of 2014 and seek potential approval of the first novel pain therapy of the morphine class to be developed in a number of years with an officially recognized new chemical structure."

KP201 is in development for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induce
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Investor-Edge has initiated coverage on the following ... Pharmaceuticals Inc. (NASDAQ: VRTX ), Alexion Pharmaceuticals ... (NASDAQ: PPHM ), and StemCells Inc. (NASDAQ: ... accessed at: http://investor-edge.com/register . The US ... positive note as the Dow Jones Industrial Average finished ...
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... addition of the "Global DNA Diagnostics Market ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020" report to their offering. ... diagnostics Market (products, applications, techniques, end users and ...
(Date:10/22/2014)... 2014 Shimadzu Scientific Instruments introduces its ... for the pain management and clinical markets. The software ... review by allowing users to highlight and review results ... QuantAnalytics allows analysts to filter results by group or ... by eliminating the need to sift through analytes of ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Grace Century, ... and healthcare projects, announces the addition of Dr. ... to its advisory team. Dr. Siddiqui will provide further ... , A graduate of University College Medical School ... degreed in medicine in 2001. With further certification as ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... NOVATO, Calif., Sept. 2 BioMarin,Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company,update at the Morgan ... September 9, 2008 at 1:35 p.m. ET., Interested ... conference,call via the investor section of the BioMarin website, ...
... Signalife, Inc. (Amex:,SGN) announced earlier today that ... of the market, regarding the law firm of ... Signalife, Inc. is a life sciences company focused ... continuous biomedical signal,monitoring. Signalife uses its patented signal ...
... SAN DIEGO, Sept. 2 Halozyme Therapeutics,Inc. ... developing and,commercializing products targeting the extracellular matrix, ... Vice President,Research, Michael J. LaBarre, PhD, Vice ... President, Legal., "Halozyme is committed to ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Global Healthcare Conference 2Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 3Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 4
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... The American Dietetic Association has released an updated ... if well-planned, are healthful and nutritious for adults, infants, ... chronic diseases including heart disease, cancer, obesity and diabetes. ... the Journal of the American Dietetic Association , ...
... have uncovered new evidence suggesting that damage to nerve ... body,s natural mechanism for repair of the nerve coating ... today, July 1, 2009, in the print edition of ... at the University of California, San Francisco and University ...
... The Netherlands: For the first time, researchers have been ... failure of IVF treatment in blood. Dr. Cathy Allen, from ... of the European Society of Human Reproduction and Embryology today ... IVF works for some patients but not for others. ...
Cached Biology News:ADA releases updated position paper on vegetarian diets 2MS study offers theory for why repair of brain's wiring fails 2MS study offers theory for why repair of brain's wiring fails 3Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: cap, ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... General description: Workstation for PCR set-up ... 96 MicroWell format to hold 0.2 ml PCR tubes, ... compatible with automated handling systems Removable tray ... Compatible with V-bottom 0.2 ml tube block thermal ...
Biology Products: